An Independent International Scientific Web Site to Promote Intellectual Values

Home

TMS: An effective treatment for depression

Gagandeep Kaur, M.D., Rif S. El-Mallakh, M.D., Ahmad S. Bashir, M.D., Paul Kensicki, M.D., Steven Lippmann, M.D.

Abstract. Transcranial magnetic stimulation (TMS) is a promising therapeutic option in psychiatry, especially for patients with treatment resistant affective illnesses. Some depressed people who are refractory to conventional therapies improve with TMS. Complications or side effects are uncommon. Administration requires no anesthesia, so patients can be fully alert and decisional during and after each session. TMS can be an acute therapy and also be a long-term intervention.
Read more...

Translating the Evidence of Prescription Monitoring Program

Yulin Chu, N.P.

Addiction, overdoses and deaths involving nonmedical prescription drug use, especially narcotic pain relievers, have risen dramatically over the last decade (Prescription Drug Monitoring Program Center of Excellence at Brandeis [PDMPCE], 2014).  In 2010, drug related poisonings were the leading cause of death due to unintentional injuries in the US. The number of overdose deaths involving prescription opioids has more than tripled since 1999; in 2010 these deaths were greater than those involving heroin and cocaine combined. A study estimated that in 2006 the total cost in the US of nonmedical use of prescription opioids was $53.4 billion (PDMPCE, 2014).
Read more...

The New York Declaration

Leo Sher, M.D.

Recently, four members of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Men’s Mental Health developed the statement on the future directions concerning the impact of childhood and adolescent adversities in the field of men’s mental health. The article, “Future directions concerning the impact of childhood and adolescent adversities in the field of men’s mental health: The New York Declaration” has been published in “Frontiers in Public Health” under the terms of the Creative Commons Attribution License. Therefore, we can publish this article on the website, www.internetandpsychiatry.com
Read more...

The Madrid Declaration

Leo Sher, M.D

In 2013, the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Men’s Mental Health was created. Currently, the Task Force consists of the following academics: Chair: Leo Sher (USA); Co-Chair: Zoltan Rihmer (Hungary); Secretary: Timothy R. Rice (USA); Members: Mikkel Arendt (Denmark), M. Dolores Braquehais (Spain), Javier Didia-Attas (Argentina), Masahito Fushimi (Japan), Julia Golier (USA), Jose de Leon (USA), Shih-Ku Lin (Taiwan), J. John Mann (USA), Anne-Maria Möller-Leimkühler (Germany), Alexander Neumeister (USA), Jorge Ospina-Duque (Colombia), Carlos Roncero (Spain), Wolfgang Rutz (Sweden), Robert G. Stern (USA), Nestor Szerman (Spain).
Read more...

Artificial sweeteners: beneficial or added concerns?

Pramod Kayathi, M.D., Gurpreet Singh, M.D., Vivek C. Shah, M.D., Steven Lippmann, M.D.   

Introduction
Artificial sweeteners are synthetic or natural substances utilized as a substitute for table sugar. These sweeteners contain few calories, thus they are a frequent dietary choice. Since they are sweeter than sucrose, small amounts of these substances are taste-equivalent to sugar. Approximately 180 million Americans consume these sweeteners daily in “sugar-free” foods and beverages (1). They have gained popularity due to being marketed as low calorie options, thus expected to minimize obesity as a health-aid for weight loss or control. Recently, however, there is inconclusive data suggesting that such sweeteners might even induce weight gain.
Read more...

Health disparities in Alzheimer’s Disease

Yulin Chu, N.P.

Racial Disparity in AD
Per U.S. Department of Health and Human Services (HHS) (2013) reports, some populations are unequally burdened by Alzheimer’s disease (AD), including racial and ethnic minorities. According to Alzheimer’s Association (AA) reports, the likelihood of developing AD and other dementias is overall at two times more likely for African Americans and about 1.5 times more likely for Hispanics than whites (U.S. Medicine, 2010).

In the past decade, many studies in the U. S. reported the similar results.  Hispanics had an earlier age of onset (Alzheimer symptoms may strike Latinos almost seven years before white Americans) and greater severity of Alzheimer’s symptoms at their initial evaluation.
Read more...

Propranolol: A possible therapeutic option in PTSD?

Manasa Enja, M.D., Suneela Cherlopalle, M.D., Murali K. Kolikonda, M.D., Steven Lippmann, M.D.

Introduction
People with posttraumatic stress disorder (PTSD) repeatedly re-experience the agony of past emotionally upsetting circumstances. PTSD is characterized by hypervigilance, intrusive thoughts, sleep disturbance, and avoidance behavior towards reminders of past trauma. These symptoms often lead to social, occupational, and/or interpersonal dysfunction.

Catecholamines in PTSD
Epinephrine and norepinephrine are the primary catecholamines secreted in response to stress.
Read more...

New concerns about caffeine products

Gurpreet Singh, M.D., Pramod Kayathi, M.D., Vivek C. Shah, M.D., Steven Lippmann, M.D.

Introduction
Caffeine is a naturally occurring psychoactive substance found in many different plants. It is a powerful stimulant, marketed as a dietary supplement, and occurs in beverages such as coffee, tea, cola, energy drinks or pills, and chocolate products, etc.  Unlike some other psychoactive drugs, caffeine is legal and unregulated. About  80% of American adults ingest caffeinated products at an average intake of approximately 200mg per day (1).  Caffeine utilization at under 500mg is commonly considered to be safe, and there is documented safety at 300mg or below per day (2).
Read more...